Literature DB >> 956664

Production and characterisation of antisera to diphenylhydantoin suitable for radioimmunoassay.

J W Paxton, F J Rowell, J G Ratcliffe.   

Abstract

The effect of carrier protein, nature of hapten-carrier bridge, and density of hapten substitution on the immunogenicity of diphenylhydantoin (DPH) derivatives in rabbits is described. DPH-3-valerate-bovine serum albumin (BSA) with a hapten: protein ratio of 27: 1 yields antisera of high titre and specificity for DPH. An antiserum to DPH-valerate-BSA was employed to develop a rapid, sensitive, one stage double antibody radioimmunoassay suitable for clinical application to serum, saliva, and urine samples. The assay, using 14C-DPH as tracer, is accurate and precise over the range 0.5--50 mug DPH per ml. Results by radioimmunoassay correlate closely with those obtained by gas-liquid chromatography (r = 0.97).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956664     DOI: 10.1016/0022-1759(76)90026-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Letter: Antipyrine half life and clearance in clinical practice.

Authors:  B Whitling; M Ullah; P A Meredith
Journal:  Br Med J       Date:  1976-08-21

2.  Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring.

Authors:  F Kamali; S H Thomas
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay.

Authors:  J W Paxton; B Whiting; K W Stephen
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

4.  Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.

Authors:  J W Paxton; F Rowell; J G Ratcliffe; D G Lambie; R Nanda; I D Melville; R H Johnson
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

5.  Alterations of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy.

Authors:  W H Steele; J R Lawrence; H L Elliott; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.